S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
UK
LSE
Biontech Se (0A3M)
Biontech Se (0A3M) News

0A3M

Biontech (0A3M)

Biontech Se

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0A3M

1

Date	Time	Source	Headline	Symbol	Company
04/22/2024	5:45AM	UK Regulatory	BioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen Fortschritt	LSE:0A3M	Biontech Se
04/22/2024	5:45AM	UK Regulatory	BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024	LSE:0A3M	Biontech Se
04/07/2024	1:00PM	UK Regulatory	Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer	LSE:0A3M	Biontech Se
04/07/2024	1:00PM	UK Regulatory	Drei-Jahres-Follow-up-Daten aus Phase-1-Studie mit individualisiertem mRNA-Immuntherapie-Kandidaten zeigen eine anhaltende Immunantwort und ein verringertes Rückfallrisiko bei einigen Patienten mit reseziertem Bauchspeicheldrüsenkrebs	LSE:0A3M	Biontech Se
03/20/2024	5:15AM	UK Regulatory	BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update	LSE:0A3M	Biontech Se
03/20/2024	5:15AM	UK Regulatory	BioNTech veröffentlicht Ergebnisse für das vierte Quartal und das Geschäftsjahr 2023 sowie Informationen zur Geschäftsentwicklung	LSE:0A3M	Biontech Se
03/20/2024	5:00AM	UK Regulatory	BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer	LSE:0A3M	Biontech Se
03/20/2024	5:00AM	UK Regulatory	BioNTech beruft Annemarie Hanekamp als Chief Commercial Officer in den Vorstand	LSE:0A3M	Biontech Se
03/11/2024	6:45AM	UK Regulatory	BioNTech präsentiert auf der AACR-Jahrestagung 2024 klinische Daten-Updates zu mRNA-basierten und zielgerichteten Onkologie-Kandidaten	LSE:0A3M	Biontech Se
03/11/2024	6:45AM	UK Regulatory	BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024	LSE:0A3M	Biontech Se
03/07/2024	5:45AM	UK Regulatory	BioNTech gibt geplanten Ruhestand von Sean Marett bekannt	LSE:0A3M	Biontech Se
03/07/2024	5:45AM	UK Regulatory	BioNTech Announces Planned Retirement of Sean Marett	LSE:0A3M	Biontech Se
03/06/2024	5:45AM	UK Regulatory	BioNTech veröffentlicht am 20. März 2024 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2023 und informiert über operativen Fortschritt	LSE:0A3M	Biontech Se
03/06/2024	5:45AM	UK Regulatory	BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024	LSE:0A3M	Biontech Se
02/08/2024	4:45AM	UK Regulatory	BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs	LSE:0A3M	Biontech Se
02/08/2024	4:45AM	UK Regulatory	BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme	LSE:0A3M	Biontech Se
01/31/2024	5:45AM	UK Regulatory	BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305	LSE:0A3M	Biontech Se
01/31/2024	5:45AM	UK Regulatory	BioNTech und DualityBio erhalten Fast-Track-Status der FDA für innovativen Antikörper-Wirkstoff-Konjugat-Kandidat BNT325/DB-1305	LSE:0A3M	Biontech Se

Showing the most relevant articles for your search:LSE:0A3M

1

AMC Entertainment

1812 Brewing (PK)

Innovation Pharmaceuticals (CE)

Virexit Technologies (PK)

NaturalShrimp (QB)

Innerscope Hearing Techn... (PK)

Canopus Biopharma (PK)

TPT Global Tech (CE)

Asia Broadband (PK)

Northwest Biotherapeutics (QB)

NioCorp Developments

Fannie Mae (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions